(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr6.30 | 3.46% | 61.1% |
| MEDISTIM (MEDI.OL) | kr175.50 | 2.56% | 27.12% |
| UCB (UCB.BR) | €120.35 | 1.12% | 3.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and America. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary uses. Its products include Rivent that offers image enhancement and visualization solutions for ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, a 2D image enhancement product for handheld units; and Rivent 3D, an image enhancement solution for 3D ultrasound. The company also provides Altumira/Altumira Plus, an artificial intelligence-powered image enhancement product for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.42.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 15. Meaning, the purchaser of the share is investing kr15 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Yearly Top and Bottom Value
CONTEXTVISION’s stock is valued at kr6.30 at 22:30 EST, way below its 52-week low of kr7.80.
More news about CONTEXTVISION.
2. MEDISTIM (MEDI.OL)
2.56% Forward Dividend Yield and 27.12% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. It operates through Sale of Own Products; and Sale of 3. Party Products segments. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; MiraQ Ultimate, which uses flow measurement and ultrasound imaging probes to provide a complete assessment; and imaging probes for intraoperative use. It also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical devices. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.67.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 30.95. Meaning, the purchaser of the share is investing kr30.95 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.12%.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.50%, a negative 0.28%, and a positive 1.73%.
MEDISTIM’s highest amplitude of average volatility was 1.63% (last week), 1.98% (last month), and 1.73% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr175.50 at 22:30 EST, way below its 52-week high of kr303.00 and above its 52-week low of kr169.50.
More news about MEDISTIM.
3. UCB (UCB.BR)
1.12% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.76.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 68.38. Meaning, the purchaser of the share is investing €68.38 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 26, 2024, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 1.12%.
Moving Average
UCB’s worth is way above its 50-day moving average of €107.97 and way higher than its 200-day moving average of €85.79.
More news about UCB.
